Video

Dr. Scott on Connect MDS and AML: A Disease Registry

Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

Scott says this large, national registry will collect information on biological markers and prognostic markers from patients with MDS. From this registry, researchers will be able to get a better idea of how to predict long-term outcomes. The registry will also include patient samples, Scott says, so that researchers can look at a variety of factors that can be involved in prognosis and response to different types of treatments.

<<<

View more from the 2015 MDS Symposium

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP